Tag Archive for: NEPC

Deciparticle Everolimus: Reviving mTOR Inhibition for Neuroendocrine Prostate Cancer?

/in , /by

Sapu-003, a nanoparticle-formulated version of everolimus delivered via a new platform (Deciparticle) has received approval for first-in-human Phase 1 testing in breast cancer patients, representing a major advance in intravenous oncology drug delivery. Unlike the standard oral everolimus tablet, which achieves only 10-20% bioavailability due to extensive first-pass metabolism and gastrointestinal degradation, the Deciparticle platform […]

Read more

Phase 1/2 Trial for MK-6070 (Gocatamig): A Promising Trispecific T-Cell Engager for Neuroendocrine Cancers

/in , , /by

MK-6070 (Gocatamig) is an engineered trispecific T-cell engager designed to target a protein called DLL3, which is predominantly found on certain aggressive neuroendocrine tumors, including prostate cancer. This molecule works by simultaneously binding to DLL3 on tumor cells, the CD3 receptor on T cells, and serum albumin, which extends the drug’s circulation time in the […]

Read more

Phase 1/2 Trial: MT-4561 Targeting BRD4 in Metastatic Prostate Cancer and Neuroendocrine Prostate Cancer

/in , , , /by

NEPC

Read more

Preclinical: Targeting NSD2, a Promising Strategy Against Treatment-Induced Neuroendocrine Prostate Cancer

/in /by
Read more